Brooks S C, Rozhin J, Pack B A, Horn L, Godefroi V C, Locke E R, Zemlicka J, Singh D V
J Toxicol Environ Health. 1978 Mar-May;4(2-3):283-300. doi: 10.1080/15287397809529662.
There has been an increasing interest in the sulfate conjugates of estrogens as important metabolites in steroid hormone homeostasis and activity. In women estrogen sulfates have been known as major components of plasma originating from ovarian secretion and hepatic metabolism. However, only recently has the capacity to sulfurylate estrogens been demonstrated in estrogen target tissues. Porcine uterus estrogen sulfotransferase appears only after the first complete estrous cycle. Following puberty, gilt uterine sulfurylation of estrogens is extremely active during diestrus, whereas estrogen sulfotransferase is not present during estrus. This cycling of estrogen sulfurylation in porcine and human uteri can be related directly to plasma progesterone levels. Rodent and human mammary tumors are also highly active in both steroid alcohol and estrogen sulfotransferases. Unlike uterine sulfotransferases, these enzymes are apparently stimulated by factors that appear following ovariectomy. The function of estrogen sulfurylation by target tissues remains obscure. However, recent investigations have indicated that the cyclic variation in endometrial estrogen sulfurylation may control the availability of 17 beta-estradiol to the cytoplasmic receptor. This premise is supported by the continued high estrogen sulfurylation activity and low nuclear receptor levels during implantation in fertilized gilts and sows. Utilizing purified bovine adrenal sulfotransferase, the substrate and inhibitor requirements were determined for this enzymes. It was also possible to design a specific inhibitor that will block estrogen sulfurylation without interfering with the receptor binding and nuclear migration of physiological levels of 17 beta-estradiol. This inhibitor, 3-methoxy-4-nitroestrone, will help in establishing the role of uterine and mammary estrogen sulfurylation.
雌激素的硫酸酯作为类固醇激素稳态和活性中的重要代谢产物,已引起越来越多的关注。在女性中,雌激素硫酸酯一直被认为是源自卵巢分泌和肝脏代谢的血浆主要成分。然而,直到最近才在雌激素靶组织中证实了硫酸化雌激素的能力。猪子宫雌激素硫酸转移酶仅在第一个完整发情周期后出现。青春期后,未孕母猪子宫在发情间期对雌激素的硫酸化极为活跃,而在发情期则不存在雌激素硫酸转移酶。猪和人类子宫中雌激素硫酸化的这种周期性变化可能与血浆孕酮水平直接相关。啮齿动物和人类乳腺肿瘤在类固醇醇和雌激素硫酸转移酶方面也具有高度活性。与子宫硫酸转移酶不同,这些酶显然受到卵巢切除后出现的因素的刺激。靶组织中雌激素硫酸化的功能仍不清楚。然而,最近的研究表明,子宫内膜雌激素硫酸化的周期性变化可能控制17β-雌二醇向细胞质受体的可用性。受精的未孕母猪和母猪在着床期间持续的高雌激素硫酸化活性和低核受体水平支持了这一前提。利用纯化的牛肾上腺硫酸转移酶,确定了该酶的底物和抑制剂需求。还能够设计一种特异性抑制剂,该抑制剂将阻断雌激素硫酸化,而不干扰生理水平的17β-雌二醇的受体结合和核迁移。这种抑制剂,3-甲氧基-4-硝基雌酮,将有助于确定子宫和乳腺雌激素硫酸化的作用。